EICHORCondition: Systemic Lupus Erythematosus · Sponsor: Monash University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE). SLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe manifestations of SLE are the accrual of irreversible organ damage, especially renal and central nervous system (CNS) involvement. As there is no effective targeted monotherapy for SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and inexorably accrue permanent organ damage over time. The diversity of clinical features of active SLE has made quantification of disease activity problematic. Although there are a number of published systems in use to measure SLE disease activity, there are widely acknowledged problems with these instruments. Published definitions of remission are so stringent that they are met by less than 5% of pat…
This description comes directly from the study's public registry record.
Eric F Morand · + 61 3 8572 2650 · eric.morand@monash.edu
Rangi K KANDANE-RATHNAYAKE · + 61 3 8572 2561 · Rangi.Kandane-Rathnayake@monash.edu
Always discuss trial participation with your own doctor first.
| Rheumatology Unit, Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Department of Rheumatology, Flinders Medical Centre | Adelaide, South Australia, Australia | Recruiting |
| School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences | Clayton, Victoria, Australia | Recruiting |
| Department of Rheumatology, St Vincent's Hospital (Melbourne) | Fitzroy, Victoria, Australia | Recruiting |
| Department of Rheumatology and Immunology, People's Hospital Peking University Health Science Center | Beijing, Western District, China | Recruiting |
| Rheumatology and Immunology department, Peking University First Hospital | Beijing, Xicheng District, China | Recruiting |
| Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong | Pok Fu Lam, Hong Kong | Active Not Recruiting |
| Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Padjadjaran University/ Hasan Sadikin General Hospital | Bandung, West Java, Indonesia | Recruiting |
| The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health | Kitakyushu, Japan | Recruiting |
| Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University | Tokyo, Japan | Recruiting |
| Institute of Rheumatology, Tokyo Women's Medical University | Tokyo, Japan | Recruiting |
| Joint and Bone Center, University of Santo Tomas Hospital | Manila, Philippines | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03138941